Altimmune’s Pemvidutide Achieves 59.1% MASH Resolution: A Potent "Defatting" Engine Faces the Fibrosis Lag Challenge These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. Phase 2b IMPACT trial data confirms best-in-class liver fat reduction, but a missed 24-week fibrosis endpoint necessitates a strategic pivot for Phase 3 design. What
News Deramiocel Achieves Statistical Significance in Phase 3 HOPE-3 Trial: 54% Slowing of Skeletal Disease Progression and Critical Cardiac Preservation Capricor Therapeutics’ pivotal data addresses previous regulatory hurdles, positioning the cell therapy as a first-in-class treatment for Duchenne cardiomyopathy.
News CervoMed’s Neflamapimod Reduces Plasma GFAP by 16% in DLB, Validating 'Bioavailability Hypothesis' for Phase 3 New biomarker data from the RewinD-LB extension confirms that optimized drug delivery reverses neuroinflammation, reviving the asset's commercial potential against a backdrop of unmet need.
